Single agent versus combination chemotherapy in recurrent cervical cancer

Journal of Obstetrics and Gynaecology Research

Volumn 24, Issue 6, 1998, Pages 401-409

  Kumar, Lalit ^a   Pokharel, Y H ^a   Kumar, S ^b   Singh, Rajveer ^b   Rath, G K ^a   Kochupillai, V ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cisplatinum; Ifosfamide; Recurrent cervical cancer; Survival

Indexed keywords

BLEOMYCIN; CISPLATIN; IFOSFAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; NAUSEA; PELVIC DISEASE; RECURRENT CANCER; UTERINE CERVIX CANCER; VOMITING;

EID: 0032441498     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.1998.tb00115.x     Document Type: Article

References (25)

1. Thigpen JT, Vance R, Punkey L, Khansur T. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 1995; 22 (suppl. 3): 16-24
2. Bonomi P, Blessing JA, Stechman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatinum dose schedules in squamous cell carcinoma of cervix. A gynecology oncology group study. J Clin Oncol 1985; 3: 1079-1085
3. Meanwell CA, Mould JJ, Blackledge G, Lawton FG, Stuart NS, Kavanagh J, Latief TN, Spooner D, Chetiyawardana AD. Phase II study of ifosfamide in cervical cancer. Cancer Treat Report 1986; 70: 727-730
4. Sutton GP, Blessing JA, McGuire WP, Patton T, Look KY. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A Gynecologic Oncology Group study. Am J Obstet Gynecol 1993; 168: 805-807
5. Cervellino JC, Araujo CE, Sanchez O, Miles H, Nishihama A. Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. Acta Oncol 1995; 34: 257-259
6. Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE, Recio FO. A phase II study of weekly cisplatin and ifosfamide in advanced or recurrent cervical carcinoma. Cancer 1993; 71: 2245-2249
7. Kumar L, Bhargava VL. Chemotherapy in recurrent and advanced cervical cancer. Gynecol Oncol 1991; 40: 107-111
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting the results of cancer treatment. Cancer 1981; 47: 207-211
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
10. Buxton EJ, Meanwell CA, Hilton C, et al. Combination bleomycin, ifosfamide and cisplatinum chemotherapy in cervical cancer. J Nat Cancer Inst 1989; 81: 359-361
11. Singhal RM, Jindel R, Gupta AK. Bleomycin, cisplatinum and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix. Ind J Cancer 1993; 30: 158-163
12. Ramm K, Vergote IB, Kaern J, Trope CG. Belomycin-ifosfamide-cisplatinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look. Gynecol Oncol 1991; 46: 203-207
13. Tay SK, Lall FM, Sob IT, Ho TH. Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma. Aust NZ Obstet Gynaecol 1992; 32: 263-266
14. Zanetta G, Leventis C, Lo Monico S, Landoni F, Marzola M, Mangioni C. Belomycin, ifosfamide and cisplatin chemotherapy in recurrent and persistent cervical cancer, a prospective study. Int J Gynaecol Cancer 1995; 5: 56-60
15. Behbakht K, Massad LS, Yordon EL, Lincoln SH, Eriksson JAH, Winkelman L, DeGeest K, Kirschner C, Wilbanks GD. A bleomycin/ ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent sqamous gynecologic cancers. Eur J Gynecol Oncol 1996; XVII: 7-12
16. Potter ME, Hatch KD, Potter MY, Shingleton NM, Baker VV. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatinum. Cancer 1989; 63: 1279-1282
17. Kredenster DC. Etoposide (VP-16), ifosfamide/ mesna and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecal Oncol 1991; 43: 145-148
18. Filtenberg TA, Hansen HH, Engelholm SA, Rorth M. A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix. Ann Oncol 1993; 4: 485-488
19. Murad AM, Triginelli SA, Ribalta JCL. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 1994; 12: 55-59
20. Smith HO, Stringer CA, Kavanagh JJ, Kavangh JJ, Gersbenson DM, Edwards CL, Wharton JT. Treatment of advanced or recurrent sqamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy. Gynecol Oncol 1993; 48: 11-15
21. Kasid U, Pjefer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A, Mark GE. Effect of antisense C raf-1 on the tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 1989; 243: 1354-1356
22. Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of cervix: A Gynecologic Oncology Group study. J Clin Oncol 1997; 15: 165-171
23. Kumar L, Grover R, Pokharel YH, Chander S, Kumar S, Singh R, Rath GK, Kochupillai V. Neoadjuvant chemotherapy in locally advanced cervical cancer: Two randomized studies. Aust NZ J Med 1998; 28: 387-390
24. Langer CJ, Godfrey S, Richter M, Dabrow M, Rosenblum N. Durable complete remission in recurrent, metastatic squamous cell carcinoma of the cervix after treatment with bleomycin, ifosfamide and cispiatin. Proc Am Soc Clin Oncol (Abst) 1995; 14: 282
25. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/ mesna associated encephalopatby. Eur J Cancer 1986; 22: 815-819